In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Study: Protein patterns help doctors distinguish bladder cancer cases:

This article was originally published in Clinica

Executive Summary

US researchers have identified a pattern of 22 proteins that could help distinguish patients with bladder cancer from individuals with other malignant and non-malignant genitourinary diseases. Their specific protein pattern model allowed them to correctly identify in urine samples between 86% and 100% of 31 patients with urothelial carcinoma, 138 people who had other genitourinary diseases, and 11 healthy individuals. The findings, by a team from the University of Virginia Health Sciences Center, in Charlottesville, appear in the March issue of The Lancet Oncology.

You may also be interested in...

QUOTED. 10 July 2020. Alison Hunt.

Women implanted with Bayer’s Essure birth-control device have significantly higher rates of pelvic pain, uterine bleeding and hypersensitivity compared to women who undergo tubal ligation, according to initial results from a government-mandated postmarket study. See what US FDA’s spokeswoman Alison Hunt said about it here.

Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix

Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.

Global Supply Chain Security Meets US Presidential Politics

Joe Biden’s presidential campaign now has a plan to address supply chains and encourage US-based manufacturing of prescription drugs. That affirms the unlikely national prominence of the issue – and reduces the chances of meaningful legislation this year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts